We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition (COSGOD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03166722
Recruitment Status : Completed
First Posted : May 25, 2017
Last Update Posted : February 11, 2022
Sponsor:
Collaborator:
Royal Alexandra Hospital
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:
The aim of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation and heart rate and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes).

Condition or disease Intervention/treatment Phase
Preterm Infant Brain Injuries Birth Hypoxia Other: Control group Device: Study group Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 655 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: investigator-initiated randomised multi-centre multinational clinical trial
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition After Birth: An Investigator-initiated Randomised Multi-centre Multinational Clinical Trial
Actual Study Start Date : September 20, 2017
Actual Primary Completion Date : January 31, 2022
Actual Study Completion Date : February 10, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Arm Intervention/treatment
Experimental: Study group: Invos 5100
Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy ("INVOS 5100" ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine.
Device: Study group
Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring

Active Comparator: Control group: Routine care
Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
Other: Control group
SpO2 and HR monitoring and routine treatment during immediate transition




Primary Outcome Measures :
  1. Mortality and/or occurrence of cerebral injury [ Time Frame: up to 19 weeks after birth ]
    Number of patients, who die or have intraventricular hemorrhage or have periventricular leucomalacia


Secondary Outcome Measures :
  1. Frequency of neonatal morbidities [ Time Frame: up to 19 weeks after birth ]
    Number of patients, who have infection and/or sepsis and/or necrotizing enterocolitis bronchoplumonary dysplasia, retinopathia prematurorumand/or bronchoplumonary dysplasia and /or retinopathia prematurorum

  2. Sex [ Time Frame: up to 19 weeks after birth ]
    Number of male and female patients, who die or have intraventricular hemorrhage or have periventricular leucomalacia

  3. Gestational age [ Time Frame: up to 19 weeks after birth ]
    Number of patients with less than 28 weeks of gestation and more than or equal 28 weeks of gestation, who die or have intraventricular hemorrhage or have periventricular leucomalacia



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Minute to 15 Minutes   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Preterm neonates less than completed 32 weeks,
  • Decision to conduct full life support,
  • Written informed consent.

Exclusion Criteria:

  • No decision to conduct full life support,
  • No written informed consent,
  • Congenital malformation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03166722


Locations
Layout table for location information
Austria
Department of Pediatrics, Medical University of Graz
Graz, Styria, Austria, 8036
Medical University Innsbruck
Innsbruck, Austria
Medical University Vienna
Vienna, Austria
Canada, Alberta
Royal Alexandra Hospital
Edmonton, Alberta, Canada, T5H 3V9
Germany
Universitätsklinikum Freiburg
Freiburg, Germany
Centre for Pediatric Clinical Studies
Tübingen, Germany
Ireland
University College Cork
Cork, Ireland
Italy
Ospedale dei Bambini "V.Buzzi" Milano
Milano, Italy
Institute for Maternal and Child Health, IRCCS Burlo Garofolo
Trieste, Italy
Poland
Poznan University of Medical Sciences
Poznań, Poland
Uniwersytetu Medycznego im. Karola Marcinkowskiego
Poznań, Poland
Slovenia
University Medical Centre Ljubljana
Ljubljana, Slovenia
Sponsors and Collaborators
Medical University of Graz
Royal Alexandra Hospital
Investigators
Layout table for investigator information
Principal Investigator: Gerhard Pichler, MD Medical University of Graz, Austria
Principal Investigator: Georg M Schmölzer, MD, PhD Royal Alexandra Hospital, Edmonton, Canada
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT03166722    
Other Study ID Numbers: COSGOD Phase III
First Posted: May 25, 2017    Key Record Dates
Last Update Posted: February 11, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The demographic data and data of primary and secondary outcome will be stored at and available form the Institut for Medical Informatics, Statistics und Documentation, Medical University of Graz, Austria
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: After publication of primary and secondary outcome
Access Criteria: On demand

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Premature Birth
Hypoxia
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Signs and Symptoms, Respiratory